Zhifei Bio's herpes zoster vaccine cleared for clinical trials

Chongqing Zhifei Biological Products announced that its subsidiary, Zhifei Longkema, has received approval from the National Medical Products Administration for clinical trials of its recombinant herpes zoster vaccine (CHO cells). The trials will focus on individuals aged 40 and above. The vaccine utilizes Zhifei's independently developed BC02 adjuvant system, aiming for enhanced immune response and prolonged protection. The company emphasizes its multi-pronged approach to vaccine development, including mRNA technology, and expresses its commitment to advancing research. While the approval strengthens their pipeline, the company cautioned that trial outcomes and product launch remain uncertain.